18F-FDG-PET of musculoskeletal tumors: A correlation with the expression of glucose transporter 1 and hexokinase II

Annals of Nuclear Medicine

Volumn 22, Issue 8, 2008, Pages 699-705

  Hamada, Kenichiro ^a,b   Tomita, Yasuhiko ^a   Qiu, Ying ^b   Zhang, Binglin ^b   Ueda, Takafumi ^c   Myoui, Akira ^b   Higuchi, Ichiro ^b   Yoshikawa, Hideki ^b   Aozasa, Katsuyuki ^b   Hatazawa, Jun ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Glucose transporter 1; Hexokinase II; Maximum standardized uptake values; Musculoskeletal tumor; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE ISOENZYME; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOACCUMULATION; BONE TUMOR; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE TUMOR; MUSCULOSKELETAL SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; STANDARDIZATION; TISSUE DIFFERENTIATION; CHILD; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HUMANS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 55349095493     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-008-0173-9     Document Type: Article

References (22)

1. L.G. Strauss P.S. Conti 1991 The applications of PET in clinical oncology J Nucl Med 32 623 648
2. I. Ak M.P. Stokkel E.K. Pauwels 2000 Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours J Cancer Res Clin Oncol 126 560 574
3. R.S. Brown T.M. Goodman K.R. Zasadny J.K. Greenson R.L. Wahl 2002 Expression of hexokinase II and Glut-1 in untreated human breast cancer Nucl Med Biol 29 443 453
4. A. Waki Y. Fujibayashi A. Yokoyama 1998 Recent advances in the analyses of the characteristics of tumors on FDG uptake Nucl Med Biol 25 589 592
5. F. Dehdashti B.A. Siegel L.K. Griffeth M.J. Fusselman D.D. Trask A.H. McGuire 1996 Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-d-glucose Radiology 200 243 247
6. M. Schulte D. Brecht-Krauss B. Heymer A. Guhlmann E. Hartwig M.R. Sarkar 2000 Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET J Nucl Med 41 1695 1701
7. A. Dimitrakopoulou-Strauss L.G. Strauss T. Heichel H. Wu C. Burger L. Bernd 2002 The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions J Nucl Med 43 510 518
8. R.T. Watson J.E. Pessin 2001 Intracellular organization of insulin signaling and GLUT4 translocation Recent Prog Horm Res 56 175 193
9. S.P. Mathupala A. Rempel P.L. Pedersen 1997 Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase J Bioenerg Biomembr 29 339 343
10. M. Mamede T. Higashi M. Kitaichi K. Ishizu T. Ishimori Y. Nakamoto 2005 [18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung Neoplasia 7 369 379
11. T. Tohma S. Okazumi H. Makino A. Cho R. Mochiduki K. Shuto 2005 Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer Hepatogastroenterology 52 486 490
12. T.C. Yen L.C. See C.H. Lai C.W. Yah-Huei K.K. Ng S.Y. Ma 2004 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression J Nucl Med 45 22 29
13. A.L. Folpe R.H. Lyles J.T. Sprouse E.U. Conrad III J.F. Eary 2000 (F-18) Fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma Clin Cancer Res 6 1279 1287
14. J. Aoki H. Watanabe T. Shinozaki K. Takagishi H. Ishijima N. Oya 2001 FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions Radiology 219 774 777
15. T. Higashi T. Saga Y. Nakamoto T. Ishimori M.H. Mamede M. Wada 2002 Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer J Nucl Med 43 173 180
16. W.H. Lewis 1927 The vascular pattern of tumors Bull Johns Hopkins Hosp 41 156 162
17. J.C. Sandison 1928 Observations on the growth of blood vessels as seen in the transparent chamber introduced into the rabbit's ear Am J Anat 41 475 496
18. J.C. Underwood I. Carr 1972 The ultrastructure and permeability characteristics of the blood vessels of a transplantable rat sarcoma J Pathol 107 157 166
19. L.S. Heuser F.N. Miller 1986 Differential macromolecular leakage from the vasculature of tumors Cancer 57 461 464
20. H.F. Dvorak J.A. Nagy J.T. Dvorak A.M. Dvorak 1988 Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules Am J Pathol 133 95 109
21. H. Maeda J. Fang T. Inutsuka Y. Kitamoto 2003 Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int Immunopharmacol 3 319 328
22. H. Maeda J. Wu T. Sawa Y. Matsumura K. Hori 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 271 284